A MESSAGE FROM THE PRESIDENT

I would like to thank you for the opportunity to lead ARVO, the largest vision research society in the world. As a member of the Board of Trustees for the past five years, I have been gratified by the accomplishments of the organization. We have made significant advances and are well-positioned for the future.

Membership: For the first time, our membership is well over 11,000. Each Section is experiencing growth with three Sections having more than 1,400 members each. This is emblematic of not only a healthy association, but also a healthy discipline as more researchers enter the field of vision research.

ARVO is a global community: As the Association has grown, international representation in the membership has remained constant at 42 percent. This also shows the health of vision research and the exciting work that is being accomplished around the globe. As part of the strategic planning process, there is an active attempt to better serve our international members. We are working to improve ARVO support of international advocacy initiatives and to better serve our international members at the local level. Over the next two years, ARVO will be present at meetings in Singapore, India, Australia, Portugal, Chile, and Brazil, co-sponsoring the meetings of other regional and global vision research organizations. We encourage international members to volunteer for ARVO committees in order to participate in the activities and set the direction of the Association.

ARVO provides a vibrant network: We had record attendance at the Annual Meeting this year. Anyone who attended the meeting is well aware of the incredible sight of 9,150 attendees descending on the Fort Lauderdale Convention Center. The Annual Meeting has grown into a global event with significant impact on the present and future of vision research. Beyond the scientific program, activities for basic and clinical department chairs, research administrators, members-in-training, high school students, and the media rounded out a five day program that was one of the most exciting ever. On page 17, you will find a report from the Long Range Planning Committee that outlines a number of ideas that the Program Committee will implement over the next few years to further enhance the program.

With growth comes challenge and opportunity for the future. We can meet this challenge only with active participation from the membership. Through the strategic planning process, we are addressing member concerns transmitted through a full membership survey. We welcome continued membership input as we try to continuously improve ARVO.

Sincerely,

Gary W. Abrams, MD
ARVO President

continued on page 16

ARVO Expands Educational Programs

ARVO continues to collaborate with other societies and co-sponsor symposia at other meetings, including:

Technology in Ophthalmology: New Treatment Strategies

The Ophthalmologist’s View of Genetics

Aberrometry, Refractive Surgery and Adaptive Optics: Current Thinking and Future Possibilities

Pan-American Association of Ophthalmology, March 18-21, 2005, Santiago, Chile

American Association of Anatomists, April 2-6, 2005, San Diego, California.
Cellular Pathways in Photoreceptor Neurodegeneration

Watch for official announcements for all of these programs on the ARVO Web site and ARVO E-mail blasts.

IN THIS ISSUE

ARVO Elections ................. 2
ARVO 2005 Annual Meeting ...... 6-7,9
ARVO Advocacy .................. 10
News from NEI/NIH ............... 11-13
IOVS .......................... 15
ARVO Awards .................... 19
2004 - 2005 Officers
Gary W. Abrams, MD
President

Thomas Yorio, PhD
Vice President

Larry J. Takemoto, PhD
President-Elect

Joel M. Miller, PhD
Vice President-Elect

Steven E. Wilson, MD
Vice President-Elect

Sally S. Atherton, PhD
Immediate Past President

Paul L. Kaufman, MD
Executive Vice President

ARVO Office
Joanne G. Angle
Executive Director

Kimberly M. O’Sullivan
Publications Coordinator

12300 Twinbrook Parkway, Suite 250
Rockville, MD 20852-1606
Phone: (240) 221-2900
Fax: (240) 221-0370

TIME TO RENEW YOUR MEMBERSHIP! AVOID THE LAST MINUTE RUSH BY RENEWING TODAY!!
Renewal notices have been mailed and this is the only printed notice you will receive.
The easiest way to pay your dues is online at www.arvo.org using a Visa or MasterCard. Remember, 2005 dues must be paid before you can access the abstract submission site.

ARVO ELECTIONS


Barry S. Winkler, PhD, from the Eye Research Institute of Oakland University in Rochester, MI, was elected to a five-year term as RC Trustee, assuming the office previously held by Joseph C. Besharse, PhD, of University of Wisconsin-Milwaukee Medical School.

Dr. Winkler is Professor of Biomedical Sciences in the Eye Research Institute of Oakland University. He has been an ARVO member since 1972. Dr. Winkler served as a member and chairperson of the National Institutes of Health Visual Sciences C. Study Section (1990-1995) and as a member of the Editorial Board of Investigative Ophthalmology & Visual Science from 1997-2002.

His research interests include studies on models of energy metabolism in retinal neurons, glial cells and the retinal pigment epithelium, oxidation processes and retinal detachment.

Columbia University in New York, NY, was elected to a five-year term as VI Trustee, assuming the office previously held by Oliver J. Braddick, PhD of Oxford University.

Dr. Hood has been an ARVO member since 1970, attending each of the last 34 Annual Meetings and serving on the VI Planning Committee from 1978-1981. He also currently serves on the Editorial Boards of Investigative Ophthalmology & Visual Science and the Journal of Vision. His research interests include psychophysical and electrophysiological assessment of diseases of the retina and ganglion cell/optic nerve.

University of California, San Francisco and Director of the F.I. Proctor Foundation was elected to a five-year term as IM Trustee, filling the office previously held by Sally S. Atherton, PhD of the Medical College of Georgia.

Dr. Margolis served on the ARVO Program Committee from 1998-2000 and has been an ARVO member since 1984. His primary research focus is on the cellular and molecular mechanisms that regulate establishment and maintenance of latent neuronal infection with herpes simplex virus.

As an active clinician Dr. Margolis continues to pursue clinical research aimed at understanding the pathogenic mechanisms leading to atypical clinical presentations of herpes virus eye disease ■

Trustees Nominated

At their Sections’ Business Meetings, held during the 2004 Annual Meeting in Fort Lauderdale, members of the Retina Section (RE) and Pharmacology Section (PH) nominated candidates to stand for election as Trustees in 2005. The RE Section has nominated Yasuo Tano, MD and Paul Sternberg, MD while Nicholas A. Delamere, PhD and M. Christine McGahan, PhD were nominated by the PH Section.

The 2005 Trustee Election will again be conducted utilizing an online election system. This system was extremely successful when used for the 2004 Trustee Election. All members, but especially those in voting Sections, are encouraged to check their member record via the ARVO Web site and ensure that a current E-mail address is on file. This will allow voting members to receive the online notification, ballot, and voting instructions in a timely manner and to promptly record their vote without the trouble or expense of returning the paper ballot ■
2004-2005 Committee Chairs

The following individuals have been named as Chairs for ARVO Committees for the coming year:

Advocacy Committee
M. Christine McGahan, PhD

Animals in Research Committee
Jeffrey W. Kiel, PhD

Awards Committee
Robert B. Nussenblatt, MD

Commercial Relationships Committee
Robert D. Fechtner, MD

Diversity Issues Committee
Karla Zadnik, OD

Ethics and Regulation in Human Research Committee
Gary N. Holland, MD

Exhibits Committee
Thomas R. Friberg, MD

Finance Committee
Thomas Yorio, PhD

International Members Committee
Jacob Pe’er, MD

Long Range Planning Committee
Gary W. Abrams, MD

Members-in-Training Committee
Larry J. Takemoto, PhD

Professional Development and Education Committee
Marco A. Zarbin, MD, PhD

Program Committee
Paul L. Kaufman, MD

Publications Committee
David C. Beebe, PhD

Special thanks to Douglas Anderson, MD (Ethics & Regulation), Jeffrey Liebman, MD (Professional Development and Education), Patricia D’Amore, PhD (Awards) and Christopher Paterson, PhD, DSc (Publications) who completed their chair terms this year.

To learn more about the specific activities of the committees, review committee descriptions, contact committee chairs, or volunteer for a committee, visit the Committee page on the ARVO Web site at www.arvo.org/Committee/committee-home.asp.

Committee Workshops at the 2005 Annual Meeting

The following workshops organized by ARVO Committees will be held at the 2005 ARVO Annual Meeting:

Animal Welfare and Vision Research in Conjunction with the Scientists Center for Animal Welfare (SCAW)
Organized by the Animals in Research Committee

Career Development Through Networking
Organized by the Members-in-Training and Diversity Issues Committees

Regulatory and Ethical Issues in Scientific Publication
Organized by the Ethics and Regulation in Clinical Research Committee

Visit the ARVO Web site at www.arvo.org for the most up-to-date information on Committee Workshops and all other Annual Meeting related information.
New Programs Debut at 2004 Annual Meeting

Two exciting new programs debuted at the 2004 Annual Meeting.

**BASIC SCIENCE CHAIRS LUNCHEON**
A Basic Science Chairs Luncheon hosted by Sally S. Atherton, PhD featured a presentation from the National Eye Institute (NEI) Office of Extramural Research and was attended by more than 75 Chairs and Directors of Research from basic science departments, research institutes, and foundations. Dr. Atherton commented that “this is the first formal opportunity we have had to gather this group together during ARVO. It provided an excellent opportunity to connect with colleagues that may have otherwise been missed in the course of a busy week.”

**RESEARCH ADMINISTRATORS PROGRAM**
The 2004 Annual Meeting also featured a new Research Administrators Program. Coordinated by Will Darby of NEI and Tracy D. Perkins, MPH of the University of Wisconsin, this program offered Research Administrators the opportunity to attend grant writing workshops, visit with NEI and Center for Scientific Review grant administration staff, and take part in the general program of the meeting. A luncheon was also held with attendees representing more than 30 institutions and featuring presentations on the impact of HIPAA regulations on grant administration and the capabilities of the eRA Commons for monitoring and reporting grant-related activities.

Both programs have scheduled events at the 2005 ARVO Annual Meeting. Individuals interested in receiving full information on either or both events when available, should send a note of interest to rrupp@arvo.org.

Excellent Turnout at 2004 Career Fair!

An outstanding turnout of prospective employees met with potential employers at the 2004 Career Fair. Employers from academia, government and industry were anxious to share the opportunities at their organizations with the Annual Meeting attendees. Employers declared it a resounding success for identifying qualified candidates for a wide range of positions.

Plans for the 2005 Career Fair are underway, including relocating it to the registration area, adjacent to the Placement Service. For information on participating in 2005, contact bhollis@arvo.org.

Expanded Internet Access

The Cyber Café and ARVO Internet Suite, sponsored by Genera Corporation, were once again the popular gathering places at the Annual Meeting. Ten stations were added to provide even more convenient, secure Internet access than in 2003. Wireless Internet access made its debut and was a big hit. There were so many users on the first day that service was expanded for the rest of the week to accommodate the high demand. Look for even more availability and a higher level of wireless access in 2005!
Meeting attendance has grown 31 percent since 1995 when the Meeting moved to Fort Lauderdale, Florida. **BE A PART OF ANOTHER RECORD-BREAKING YEAR — ATTEND ARVO IN 2005!**

**Meeting Highlights**

**Attendance Record Set!**

Meeting attendance has grown 31 percent since 1995 when the Meeting moved to Fort Lauderdale, Florida. **BE A PART OF ANOTHER RECORD-BREAKING YEAR — ATTEND ARVO IN 2005!**

**Future ARVO Annual Meeting Dates**

- May 1 – 5 2005
- April 30 – May 4 2006
- May 6 – 10 2007
- April 27 – May 1 2008
- May 3 – 7 2009
- May 2 – 6 2010

**ARVO Members Contacted Congress from the 2004 Annual Meeting**

Attendees e-mailed hundreds of letters to their Members of Congress during the ARVO Annual Meeting. The National Alliance for Eye Vision Research (NAEVR) booth, watched over by none other than the Statue of Liberty (who also sported an "Eye Contacted Congress" button), was also a central location for attendees to learn more about voicing their concerns about adequate eye and vision research funding.

"Due to the recent release of the National Eye Institute (NEI) data on age-related eye disease, my e-mail letters requesting $711 million for the NEI carried an even more potent message," acknowledged then-ARVO President Sally S. Atherton, PhD. "I also had the chance to remind the Congressional offices about attending the May 13 AEvR-sponsored 'Aging Eye' Capitol Hill Briefing so that they could learn more about the issue," she added.

NAEVR's activities were not confined to the booth, as it sponsored a breakfast briefing and participated in the International Advocacy session. NAEVR Executive Director James Jorkasky also conferred with the ARVO Advocacy Committee on future activities.

Visit [www.eyeresearch.org](http://www.eyeresearch.org) to learn more about NAEVR's advocacy activities and to contact your Members of Congress.
Global Networking

ARVO is a global organization – 42 percent of members and 39 percent of 2004 Annual Meeting attendees are from outside the US – so it is only fitting that this year’s Annual Meeting theme is Global Networking. The continued success of ARVO and its membership relies on effective global communication, sharing of information and resources, and collaboration. The ARVO Annual Meeting already serves as an annual gathering place for the international vision research community, the perfect Global Networking spot for more than 9,000 scientists from around the world.

The Global Networking theme will be seen and experienced throughout the 2005 Annual Meeting, and will be highlighted in programs and activities such as: • Scientific Sessions – many examples of the best global collaborations • Networking Workshop – teaching scientists how to develop and maintain a network of contacts around the world • Expanded Internet Access – helping attendees maintain contact around the world • Social Events – building relationships in casual settings • Exhibits Program – establishing relationships with the many international suppliers

2005 Abstract Submissions

The online abstract submission and revision Web site opens October 15, 2004 and closes on December 3, 2004 at 11:59 PM EST. You may revise an abstract until December 5, 2004 at 11:59 PM EST. It is not revision. ARVO staff will not revise or correct abstracts.

Only an ARVO member can be a First Author on an abstract. You can become an ARVO member online at www.arvo.org. First Authors and all co-authors must include all commercial relationships in the time of submission and presentation. You must indicate the appropriate commercial relationship code and the name of any firms that correspond to the codes indicated. Paper presenters must indicate this information on a slide at the time of presentation, and poster presenters must include this information on their poster.

Online Abstract Search Program Planner & CD-ROM

The Online Abstract Search and Program Planner will be available February 24, 2005 at www.arvo.org. The CD-ROM will be mailed together with the Program Summary Book in early March (expect six weeks for delivery). Both the online and CD-ROM formats will include a searchable database of authors, titles, full text of abstracts, and other program information, including Special Interest Groups and Workshops. These programs will include advanced searching capabilities, multiple abstract printing options including full sessions or by section in PDF format. The Online Planner again provides the capability to create a Meeting itinerary which can be downloaded to a Personal Data Assistant.
ARVO has the honor and pleasure of hosting two exceptional keynote speakers at the 2005 Annual Meeting.

NIH Director Elias A. Zerhouni, MD, and Peter Agre, MD, 2003 Nobel Laureate in Chemistry, who has been an NEI grantee for his work on The Aquaporin Water Channels, will both present at the Keynote Session on Sunday, May 1, 5:15 PM – 7:15 PM.

Read a brief biography of both speakers at right.

Plan now to attend this very exciting Keynote Session, during the 2005 ARVO Annual Meeting – Global Networking!

On May 20, 2002, Dr. Elias A. Zerhouni began his tenure as the 15th Director of the National Institutes of Health. Prior to joining the NIH, Dr. Zerhouni served as executive vice dean of Johns Hopkins University School of Medicine, chair of the Russell H. Morgan department of radiology and radiological science, and Martin Donner professor of radiology and professor of biomedical engineering. Since 2000, he has been a member of the National Academy of Sciences’ Institute of Medicine.

While attending medical school at Johns Hopkins University, Dr. Peter Agre discovered a love for biomedical research. He is now Professor of Biological Chemistry and Professor of Medicine at Johns Hopkins. Among his awards, Agre was the inaugural Carl Gottschalk Lecturer for the American Physiological Society; Karolinska Research Lecturer at the Nobel Forum; and recipient of the Homer Smith Award from the American Society of Nephrology. Agre shared the 2003 Nobel Prize in Chemistry with Roderick MacKinnon of Rockefeller University.

Sunday Symposia

May 1, 2005

Clinical Trials in Low Vision: Raising the Standards Organized by the VI Section
Glucoma - From Repair to Regeneration Organized by the GL Section
Innervation of the Anterior Segment in Health and Disease Organized by the CO Section
Macular Pigment: In Vivo Measurement, Supplementation and Relationship to AMD Organized by the RE and BI Sections
Ocular Aquaporins: A Tour Through the Eye Organized by the PH Section
Parallel Processing in the Visual System Organized by the VN Section
Perception of Location at the Time of a Saccade: Psychophysics, Physiology and Models Organized by the EY Section
Photoreceptor-Retinal Pigment Epithelium Interactions Organized by the RC Section
Regulatory T Cells in Ocular Pathology Organized by the IM Section
Smoking and Age-related Macular Degeneration - Translation of Research Findings Organized by the CL and RC Sections
Transcription in the Lens Organized by the LE Section
Treatment of Ocular Hypertension to Prevent Glaucoma: Is It Necessary? Organized by the CL Section
What Can We Learn about AMD from Inherited Macular Degenerative Diseases? Organized by the RC and BI Sections

Age-related Macular Degeneration: Clinical Facts, Molecular Hypotheses, and Prospects for Treatment and Prevention

Cell Adhesion Molecules and Their Dynamic Role in Eye Development and Disease

Engineering the Eye: Artificial Vision and Tissue Regeneration

Ocular Pathology - Beyond the Eye (Ocular Findings as Markers of Systemic Diseases)

Basic/Clinical Lecture - Cellular Pathways in Photoreceptor Neurodegeneration

This symposium is jointly organized by the American Association of Anatomists

MEETING – GLOBAL NETWORKING

Plan now to attend this very exciting Keynote Session, during the 2005 ARVO Annual Meeting – Global Networking!

On May 20, 2002, Dr. Elias A. Zerhouni began his tenure as the 15th Director of the National Institutes of Health. Prior to joining the NIH, Dr. Zerhouni served as executive vice dean of Johns Hopkins University School of Medicine, chair of the Russell H. Morgan department of radiology and radiological science, and Martin Donner professor of radiology and professor of biomedical engineering. Since 2000, he has been a member of the National Academy of Sciences’ Institute of Medicine.

While attending medical school at Johns Hopkins University, Dr. Peter Agre discovered a love for biomedical research. He is now Professor of Biological Chemistry and Professor of Medicine at Johns Hopkins. Among his awards, Agre was the inaugural Carl Gottschalk Lecturer for the American Physiological Society; Karolinska Research Lecturer at the Nobel Forum; and recipient of the Homer Smith Award from the American Society of Nephrology. Agre shared the 2003 Nobel Prize in Chemistry with Roderick MacKinnon of Rockefeller University.

2005 Exhibits and ARVO Social

Don’t have enough time to visit exhibitors at the Annual Meeting? We are making it easier than ever before at the 2005 Annual Meeting. The opening ARVO Social will be located in the Exhibit Hall on Sunday, May 1, from 7:30 PM – 8:30 PM. Exhibitors will be at their booths during this special hour. Plan to stop by to meet and greet your colleagues and get better acquainted with the products and services on display.

Are there companies you would like to see included in the 2005 Exhibit Hall? Please forward suggestions to eterry@arvo.org.

MORE 2005 ANNUAL MEETING INFORMATION ON PAGE 9.
New Enhanced ARVO Career Center!

Watch for our new online Career Center coming this fall. The new site will feature advanced search capabilities to streamline the job/candidate search processes. Candidates will be able to post their Curriculum Vitae (CV), either publicly or confidentially, at no charge and receive automated E-mails when jobs meeting their criteria are posted on the system. The Career Center will feature an online application process, which will deliver a cover letter, CV and any other documents to the employer via E-mail. Candidates who choose to remain confidential will be given a blind E-mail box for responses. Employers will be able to confidentially review CV’s and will be notified when new candidates meeting their requirements post their CV’s.

Tributes – In Memoriam

We would like to pay tribute to the following ARVO members and colleagues who have passed away in the last several months. If you know of someone we have omitted, please bring it to our attention at mem@arvo.org.

Frederick A. Bettelheim
Thomas J. Byers
Charles Kelman
Ian W. McLean
Edward MacNichol
Richard L. Masland
Ekkehard Mehdorn
Nancy Rafferty
Wilbur Robison
Robert L. Smith
J. Wayne Streilein

Are you listed in our online Membership Directory? Is your information accurate?

Go to www.arvo.org to find out!

Keep the Lines of Communication Open!

ARVO relies heavily upon E-mail communications with its members. With recent advances in spam-blocking software, it is important to include arvo@arvo.org in your contact list to ensure that important information from ARVO is not blocked. ARVO never sells its E-mail list to outside parties, and typically sends only one or two E-mails to members each month.

The Summer and Winter Newsletters are the only mailed newsletters, so it is crucial that we be able to contact you by E-mail throughout the year, especially during abstract submissions, prior to the Annual Meeting, and for elections and voting.

Check your listing in the online Member Directory at www.arvo.org to make sure that your contact information is current.

If you have not been receiving E-mailed correspondence from ARVO, and wish to, contact ARVO at mem@arvo.org.

Encourage Your Colleagues to Join ARVO!

Joining ARVO is as easy as renewing online at www.arvo.org! No documentation or signatures are required; they just enter the name of their sponsoring member, and students/fellows must enter the name of their advisor. Their membership ID number will be E-mailed to them, and they will begin receiving all the benefits of being a member of the most prestigious vision research organization worldwide. Members joining for 2005 will have access to IOVS online in the month they join.

ARVO Member Receives Presidential Honor

Arnall Patz, ARVO member and recipient of both the Friedenwald and Weisenfeld Awards, was awarded the Presidential Medal of Freedom in June, considered to be the highest civilian honor.

Dr. Patz, director emeritus of the Johns Hopkins Wilmer Eye Institute, is credited with discovering the cause of retrolental fibroplasia.

President John F. Kennedy referred to the award as, “an especially meritorious contribution to the security or national interests of the United States or to world peace or to cultural or other significant public or private endeavors.”

ARVO congratulates Dr. Patz on this recognition.
ARVO has continued to see a steady growth in its membership. In 1997, we surpassed 10,000 for the first time and it has taken seven years to reach our next milestone. Today we have 11,197 members from 70 countries, with those from outside the United States comprising 42 percent of the membership. The following graphs show the growth in membership and the changing trends in Scientific Section affiliation over the past 10 years.

More 2005 ARVO Annual Meeting Information

2005 Housing Reservations
All 2005 Housing Reservation Forms that were received at the Housing Desk during the 2004 Annual Meeting have been processed and confirmations have been sent. If you have not received a confirmation for your 2005 reservation, contact the Housing Bureau via E-mail at gflhousing@broward.org or fax (954) 765-4414 or 4197 for assistance.

If you have not already made a hotel reservation for 2005, go to www.arvo.org and click on Hotel Reservations from the 2005 Annual Meeting page. Don’t wait - the best hotels fill quickly! And over 30 percent of all available rooms have already been booked. All hotels listed in the 2005 ARVO Housing block will participate in the Shuttle Bus Service - leave the driving (and parking) to us!

Program Committee Implements Changes to Annual Meeting Schedule
Resulting from their discussions held as part of the strategic planning process, the Program Committee will be introducing several new elements to the 2005 Annual Meeting Program. Sections will be allowed to use one of their allocated sessions to include a panel discussion. Two sessions will be available for Sections who wish to collaborate in programming, with no Section’s allocation being charged for the session as was the case in the past. Poster sessions and paper sessions will be a uniform length (1.75 hours). Award Lectures will be moved to the evening and the last paper and poster sessions of each day will conclude by 5:15 PM. On the last day there will be no SIGs or Workshops so that sessions can be scheduled earlier and the Meeting will adjourn at 3:15 PM. The Committee will evaluate these changes after the 2005 Annual Meeting. Comments are encouraged and may be shared with your Section’s PC members or sent directly to PC Chair Paul Kaufman.
**ARVO ADVOCACY**

The National Alliance for Eye and Vision Research Uses New National Eye Institute Age-Related Eye Disease Data in Capitol Hill Advocacy

The National Alliance for Eye and Vision Research (NAEVR) commends the National Eye Institute (NEI) and the Eye Disease Prevalence Research Group (EDPRG) for release of age-related eye disease data.

On April 12, the NEI released data (published in the April 2004 Archives of Ophthalmology) showing that more than 38 million Americans age 40 and older experience blindness, low vision, or serious age-related eye disease (see chart below). More importantly, NEI stated that these numbers will significantly increase by the year 2020 as the population ages. The data were prepared by the EDPRG, a consortium of principal investigators who have conducted population-based eye disease studies.

Concurrently, NEI also updated its estimate of the economic and societal cost of eye disease and vision impairment to $68 billion annually (previously $50 billion).

Due to the timing of this release, NAEVR incorporated these data into testimony submitted to the file of hearings held on April 21-22 by the House Labor, Health and Human Services, and Education Appropriations Subcommittee (see related story on page 12). The data were also the focus of a May 13 AERV-sponsored "Aging Eye" Briefing (see related story on page 13). NAEVR has created an "Age-related Eye Diseases Fact Sheet,” posted at www.eyeresearch.org, which has been distributed on the Hill to House and Senate Appropriators and key Caucuses, such as the Older Americans, Women's, Black, and Hispanic Caucuses (the latter since the data also show a disproportionately higher incidence of glaucoma and cataracts in the African American and Hispanic populations).

"These numbers support NAEVR’s position that the NEI should be funded at $711 million in the federal fiscal year 2005 budget so that it can continue the groundbreaking basic and translational research that is resulting in effective treatments and therapies," NAEVR Executive Director James Jorkasky.

At its late April meeting held at ARVO, the NAEVR Board adopted a resolution commending the NEI and each member of the EDPRG for their leadership in proactively examining this issue. NAEVR sent a letter of recognition to NEI Director Dr. Paul Sieving and each EDPRG member, as well as to NIH Director Dr. Elias Zerhouni.

ARVO is a founding member of NAEVR and AERV.

---

**New Resource**

A new information portal to address issues affecting the health and well-being of American Indians is now online.

This Web resource on American Indian Health, sponsored by the National Library of Medicine, is designed to bring together health and medical resources pertinent to the American Indian population including policies, consumer health information, and research. Links are provided to an assortment of documents, Web sites, databases, and other resources.


---

**Western Eye Research Conference**

Sponsored by ARVO

September 25 – 28, 2005
Laguna Beach, California

Join your fellow colleagues for four days in sunny California to discuss Regenerative Medicine.

Held at the Laguna Beach Surf and Sand Resort

For further information contact Rhonda Williams at rwilliams@arvo.org

www.arvo.org
Orienting to the NIH Roadmap

We have entered a new epoch in medicine, one with enormous potential to understand and treat even the most intractable diseases. Great progress has been made, but much work still remains. On the laboratory front, we have moved from sequencing the genome to unfolding the proteome, which will lead to a closer understanding of cellular pathways in health and disease. Wholly new research fields like nanomedicine are just now coming to life. But before we can design nanoscale machines to intervene in disease, we must first understand the sub-molecular structures inside living cells from a nanoengineering perspective. These enterprises will require expertise drawn from many disciplines.

To address these challenges, Dr. Elias Zerhouni, the director of the National Institutes of Health, launched the NIH Roadmap. The Roadmap was created to meet new research challenges that would be difficult to achieve through traditional NIH funding mechanisms. Roadmap Initiatives in general are targeting creation of national-scale infrastructure resources and hence are interdisciplinary and inter-institutional in nature. Some are on the scale of national “core” facilities that will facilitate subsequent new ventures by individual investigators conducting ever critical small-scale science in much the way the human genome project gave us the facility to manipulate individual genes efficiently and quickly in our individual laboratories.

The Roadmap has generated considerable interest across the vision research community. As the Roadmap approaches its first anniversary, a number of new funding opportunities have been announced and more will follow. The Roadmap features three large themes: New Pathways to Discovery, Research Teams of the Future, and Re-engineering the Clinical Research Enterprise. A complete overview of the Roadmap is found at: http://nihroadmap.nih.gov.

New Pathways to Discovery addresses the daunting complexity of biological systems. Among the initiatives, the NIH National Technology Centers for Networks and Pathways will develop novel, integrated and broadly applicable proteomics technologies. This will obviously benefit vision scientists working at the cell and molecular level. New molecular libraries such as PubChem will allow researchers to select from among 500,000 small molecules that have been screened for their ability to target specific cellular events, physiologic processes and disease mechanisms. PubChem is envisioned as a platform to develop new molecular therapies. A related molecular imaging initiative aims to develop probes that will improve the ability to detect and image specific molecular events within cells and systems.

The Structural Biology initiative will establish Centers for Innovation in Membrane Protein Production to yield structurally and functionally intact proteins for study. The resources provided by these membrane protein facilities could be leveraged to understand the structure of receptors and interacting proteins throughout the visual system.

NIH is organized along Institute lines, whereas Roadmap initiatives are designed to cross these boundaries. The National Eye Institute has been tasked by Dr. Zerhouni to provide programmatic leadership for the Nanomedicine Initiative. The first call for applications to establish several Nanomedicine Development Centers was announced in summer 2004. The Centers will explore the biophysical and chemical properties of intracellular structures, leading eventually to the development of radically new tools to detect and treat disease.

New and novel thinking will be required to make these and other initiatives a reality. Innovative thinking is sparked in high-risk research settings where success is not guaranteed. Some initiatives will require us to venture beyond the life sciences to incorporate expertise from diverse disciplines, such as physics, engineering and computation. The Research Teams of the Future initiative will foster high-risk, interdisciplinary research.

Interactions between basic and clinical scientists have always been an NIH goal but it needs re-emphasis and expansion, and Re-engineering the Clinical Research Enterprise will do just that. An NIH Multidisciplinary Clinical Research Workforce Training Program will train a cadre of Clinical Research Associates to meet the growing needs of translational research across the country. Common data standards and software tools for protocol preparation, IRB management, and adverse event reporting will be developed. To ease the burden of clinical trial recruitment, the Roadmap will focus on clinical trial investigator networks that include community-based physicians. The NEI and vision research community have already anticipated these opportunities by creating networks such as the Pediatric Eye Disease Investigator Group (PEIDG), composed of 60 participating sites with over 120 pediatric ophthalmologists and optometrists from academic and private practice, and by the newly launched Diabetic Retinopathy Clinical Research Network.

The Roadmap highlights the coming scientific challenges we face in transforming medicine. The Roadmap initiatives will provide new opportunities for all of science, large and small. I am confident that the vision research community will respond to these new challenges and will both contribute to and benefit greatly from the Roadmap.
Fiscal Year 2005 Budget and Appropriations Process

On February 2, the President’s Fiscal Year (FY) 2005 budget was issued (see chart below). The budget proposed a 2.9 percent increase for the NEI, or an increase of $19 million to $671.6 million. NEI is in the middle of a range of Institute increases from 2.8 to 3.1 percent. The budget also proposed an NIH increase of 2.6 percent to $28.8 billion.

Although both the Senate and House passed budget bills (March 12 and March 25, respectively) and the House passed the final conference report on May 19, at press time the Senate had not yet passed a final conference Budget Resolution. Irrespective, the House and Senate Labor, Health and Human Services, and Education (LHHS) Appropriations Subcommittees conducted hearings in April, and the House began marking up an LHHS bill in early July. The Appropriations hearings enabled NIH Director Dr. Elias Zerhouni to state his priorities for the NIH generally, and for he and NEI Director Dr. Paul Sieving to elaborate on the vital role of eye and vision research, specifically. In opening comments at the April 1 Senate LHHS Appropriations Subcommittee hearing, Chairman Arlen Specter (R-PA) joined colleagues from both sides of the aisle in recognizing the importance of the NIH and acknowledging past successful bipartisan actions that doubled the NIH budget over the past five years. They cautioned, however, that the 2.6 percent increase proposed in the President’s FY2005 budget could jeopardize the momentum of discovery.

Dr. Zerhouni cited NIH’s five priorities as chronic diseases, aging, health disparities, co-morbidities, and biodefense. Not surprisingly, eye and vision research plays a pivotal role in the success of these priorities. In fact, in response to a question about the NEI’s plans for an Age-related Macular Degeneration (AMD) Clinical Trials Network, Dr. Sieving noted the increasing incidence of AMD as the population ages, the ability to work across several Institutes due to the neurodegenerative nature of AMD, and the ability to follow up on the previous NEI-sponsored Age-related Eye Diseases Study (AREDS) that demonstrated that high levels of antioxidant nutrients and zinc significantly reduce the risk of advanced AMD.

At the April 21-22 House LHHS Appropriations Subcommittee hearings on the NIH Roadmap for Medical Research and Budget/Priorities, chaired by Cong. Ralph Regula (R-OH), Dr. Zerhouni described NEI’s research within the context of the Roadmap and trans-Institute initiatives, such as the NIH Neuroscience Blueprint, in which the NEI and nine other Institutes participate. In describing the importance of early detection and onset of co-morbidity, he praised the NEI-sponsored Early Treatment Diabetic Retinopathy Study’s identification of treatments that are 95 percent effective, while using the recently released NEI data on age-related eye disease to praise the AREDS findings.

For both hearings, NAEVR submitted a written statement by Board President Stephen J. Ryan, MD and accompanying testimony that supported FY2005 funding for the NIH and the NEI at $30 billion and $711 million, respectively. The documents are available at www.eyeresearch.org.

On July 7, the House LHHS Appropriations Subcommittee began the markup process and approved an LHHS bill that would fund the NIH and NEI at the levels proposed in the President’s budget. On July 14, these funding levels were subsequently approved by the full House Appropriations Committee, and floor action on the LHHS bill was expected in early September when the House returns after the summer recess. The Senate did not begin markups prior to the summer recess, but is expected to do so in September, possibly bundling a number of appropriations bills into an omnibus package.

Register for The Laboratory Mouse in Vision Research

The Jackson Laboratory is still accepting registrations for the The Laboratory Mouse in Vision Research, October 13-16, 2004 at The Jackson Laboratory in Bar Harbor, Maine. This meeting, sponsored by the National Eye Institute, provides an interactive forum for investigators and students working in eye research using the laboratory mouse as a genetic model system. The laboratory mouse is widely considered the premiere experimental organism for genetic studies that have implications, often direct, for human eye biology and disease.

Postdoctoral and graduate students are especially encouraged to attend. Up to twenty $500.00 travel scholarships are available for selected students. For more information on this course and the registration process, please visit www.jax.org/courses/events/coursedetails.do?id=42 or contact Barbara Donovan directly at bdonovan@jax.org.
HELD during both Older Americans Month and Healthy Vision Month, the Alliance for Eye and Vision Research (AEVR) May 13 Capitol Hill Briefing on “The Aging Eye” drew 50 Congressional staff members who were educated about the physiology and incidence of age-related eye disease. ARVO Executive Vice President Paul Kaufman, MD (University of Wisconsin at Madison) and Janine Smith, MD (NEI’s Deputy Clinical Director, Division of Epidemiology and Clinical Research) spoke, after an introduction by Cong. Ralph Regula (R-OH), Chairman of the House LHHS Appropriations Subcommittee, who emphasized the importance of medical research, generally, and eye and vision research, specifically.

Dr. Kaufman described and graphically demonstrated the physiological changes in the eye that result in age-related eye disease. In addition to reporting the top-line data from NEI’s recent study age-related eye disease study, Dr. Smith addressed the impact of vision loss on quality of life. "Blindness and loss of vision can lead to loss of independence and reduced quality of life, as well as an overall impact on health, since it can also lead to an increased risk of falls and an increased risk of depression."

Both speakers described NEI-sponsored research and clinical studies aimed at treating and potentially delaying or ultimately preventing the onset of these conditions. "People are living longer and are experiencing the changes that occur as the eye ages," said Kaufman. "With the annual economic and societal cost of eye disease and vision impairment at $68 billion and growing, spending now on eye and vision research at the NEI is a wise federal investment."

Commenting on the Briefing’s impact, NAEVR/AEVR Executive Director James Jorkasky observed that, “In addition to representation from the Appropriations Committee, we also had staff from the Older Americans, Vision, Black, and Hispanic Caucuses, which speaks volumes to the broad and significant impact of aging eye issues on public health.”

A streaming video of the event is accessible on the AgingEyeTimes.net Web site.

AEVR conducted another Capitol Hill briefing on September 8 entitled Vision Health Disparities Research, which focused on the results of the NEI-sponsored Los Angeles Latino Eye Study.

NIH Launches Expanded Web Site


Take a look at the three colorful new feature sections. Research in Action links users to cutting-edge scientific information on topics such as stem cells and genetics and offers the opportunity to meet scientists. Healthy Lifestyles connects the reader to popular topics such as weight loss while Now Online has interactive features and Web exhibits.

The newly expanded site still offers information suitable for the entire family, including children, teens, adults and senior citizens. Educators, clinicians and scientists will continue to find the site a valuable resource.

Words of Praise from Senator Specter

During the Senate’s March 11 debate on a budget resolution, LHHS Appropriations Subcommittee Chairman Arlen Specter (R-PA) introduced an amendment (which subsequently passed) to increase FY2005 NIH funding by $1.3 billion, for a total of $2 billion over FY2004 to $30 billion. In his introductory remarks, Sen. Specter stated that “NIH has made phenomenal progress against ...diseases, including glaucoma and macular degeneration” and noted that the additional funds (in part) were necessary “to launch a clinical trials network to test new therapies for age-related macular degeneration.”
In the debate over open access to scientific reports, one occasionally hears the view: “What’s all the fuss about? All serious researchers already have easy access through their institutional journal subscriptions.” A while ago I set out to test this notion. I conducted a small, informal survey to compare accessibility of open-access and restricted-access online journals in the area of vision science. Twenty-eight journals were selected, four of them open access journals, one of them the Journal of Vision. The survey was sent to 15 active vision scientists, a set designed to include a range of countries, workplaces, and employers. Each respondent was asked to try to reach the online full-text of a particular recent article in each of the twenty-eight journals, from a link provided in the survey. Respondents were asked to complete the survey either at work or at home, or both. We received 14 responses regarding access attempts from the workplace and five from home.

Overall, the success rate for restricted-access journals was 30 percent from the office and 13 percent from home. Clearly, access is not so easy, even for active researchers at prominent institutions in developed countries. And we must assume the record would be even less satisfactory for researchers at less prominent institutions or in less developed countries.

For the four free-access journals, success rates were 100 percent from both home and office. The Journal of Vision is an open and free-access publication – the full text of every article is available for free to anyone with Internet access from the moment of first publication. There are many considerations scientists must weigh in the decision of where to publish their work, but surely an important concern is whether their work will be easily accessible to everyone, anywhere, anytime.
IOVS

An Editor’s Mid-Summer Musings

June, 2004 marked the beginning of the third year that the manuscript submission and review process for IOVS has been carried out entirely online, via iovs.manuscriptcentral.com. The use of this online system has been an enormous, and unequivocal, plus for our journal. For authors, the submission process is much easier. The review process is much quicker. Since January 1, 2004, the mean time is 31.1 days, close to the best in all of biomedical science.

Communication with authors, reviewers, and Editorial Board members is easier. Costs are down, and efficiency is up.

But there are a couple of less rosy items that I’d like to bring to your attention.

The first is, that easier though the manuscript review process has become, getting willing reviewers is often difficult. For a few manuscripts, we’ve had to ask as many as 17 individuals to get just two reviewers. For several others, we’ve had to ask 10. Reviewing takes time and effort, and is a burden in the inevitably busy schedule of every successful scientist. But it is the central, most essential element in scientific publication. We are looking for ways to give incentives to reviewers, however, there’s no escaping that reviewing is a necessary job that will be with us as long as there is scientific communication.

A second concern is “gratuitous” authorship. In today’s science, there are few single-authored papers. But we receive an increasing number of manuscripts with 10, 12, or even more co-authors. What did all these people do to advance the project? The Council of Science Editors lists four criteria (see side bar). For manuscripts with 6 or more authors, we now ask that the senior author list the contributions of all of the co-authors to the work described.

Finally, and most disturbing, is the frequency of attempted “double publication.” Every peer-reviewed journal requires the authors of each submitted manuscript to attest that, “The work described herein is original. It has not been published elsewhere except as an abstract, and it is not currently under consideration for publication by another journal.” And yet, in my brief tenure as editor, we’ve had at least four instances of attempted double publication in IOVS reported by our reviewers or Editorial Board members.

Because of the seriousness of the matter, I always check these out personally. Sometimes, the concern is relatively small: a figure is copied from one paper to another without attribution. In another recent case, large sections of text and a portion of one data table were transferred verbatim from one manuscript to another (both of which were on the verge of acceptance by IOVS and another journal). “Double publication” is a serious transgression that can adversely affect an individual’s career, and we are deeply saddened when we see it.

These are the major concerns of this editor’s job. On the whole, it’s been challenging, exhilarating and, absolutely, a lot of fun. I hope that you are all having a wonderful summer, and I thank you for the tremendous support you’ve been giving to IOVS.

How to Find an ARVO Annual Meeting Abstract

Annual Meeting abstracts for 2002-2004 are available for free at IOVS Online, www.iovs.org, the official publication of record. Below are ways to search for abstracts.

1) Specify Citation: a) enter the meeting year in the “Year” window; b) if you know the E-abstract (program) number of the abstract, enter it in the “First page” window
2) Specify Authors, Keywords: type in keyword(s) in the appropriate window(s); a) wildcard search by using an asterisk, e.g., “corn*” will give results including “cornex” and “corneal”; b) narrow your search by entering information into more than one window (AND logic); c) for exact phrase searching, select the “phrase” button
3) Specify Journals to Search: select “ARVO Meeting Abstracts”
4) Click “Search”

NOTE: The “Specify DOI” and “Limit Results” fields are not available for the Meeting Abstracts search.

Special IOVS features available only online:

•Find that article! Search IOVS: full text from July 1999 to date; abstracts only from 1975-1999; Tables of Contents from 1965-1974
•Search across all journals at HighWire Press
•Register for E-alerts
•CiteTrack: E-alerting when articles of interest are published in IOVS or participating HighWire journals
•Internal article linking
•Intra-journal linking
•Reference links to PubMed Central, Medline, ISI, Inforrieve, and more
•Citation Map
•Citation Manager for references (EndNote, Reference Manager, ProCite, BibTeX, Medlars)
•E-mail articles to a friend
•Special Collections: Editorials, Lectures, New Developments, and Letters to the Editor
•Send a Letter to the Editor right from an article!
•Supplements – data tables, videos, and more
•All articles free access 12 months after publication
ARVO Expands Educational Programs

The ARVO US-Indo Workshop on Collaborative Research will be held February 10-12, 2005 in India, and April 28-29, 2005 in Fort Lauderdale. Under a cooperative agreement with NEI, these workshops will bring together a small group of researchers from the US and India to discuss the research opportunities that collaboration between the US and India could bring.

Five broad themes will be explored in preparation for broad dissemination of a white paper on potential collaborative areas:

- Molecular Genetics of Eye Disease
- Clinical Aspects of Genetics of Eye Disease
- Harmonization of Clinical Measurement Techniques and Terminology for Targeted Diseases and Structures
- Identification, Development and Exchange of Research Resources
- Translational Physiology: Bench to Bedside Application.


The inaugural conference of the ARVO/Pfizer Ophthalmics Research Institute is scheduled for April 28-30, 2005 supported by a generous grant to The ARVO Foundation by Pfizer. The conference will address the topics of Normal and Abnormal Angiogenesis, Neovascularization, and Vasoproliferation. A report on the discussions and opportunities will be widely disseminated.

The 9th Annual Vision Research Conference, co-sponsored by ARVO, will be held again in Fort Lauderdale, April 29-30, 2005 on the topic of Neuroimaging the Retina.

The biennial Western Eye Research Conference is now an ARVO sponsored meeting. It will be held September 25-28, 2005, in Laguna Beach, California, returning to the Surf and Sand Resort. The conference topic is Regenerative Medicine. To be placed on a mailing list for more information, please send your name and E-mail address to rwilliams@arvo.org.

ARVO is pleased to announce the inaugural Sarasota Eye Research Conference, Ocular Cell and Molecular Biology, to be held September 8-10, 2005, in Sarasota, Florida, at the Colony Resort, right on the beach. Conference attendance is limited. Add your name to the mailing list today by contacting rwilliams@arvo.org.

Board Stipulates Compliance with ARVO Policies

Members complained at the 2004 ARVO Annual Meeting of inadequate disclosure of commercial relationships and violations of the recording policy. The Board discussed these issues and has charged the membership to follow the policies and assist their colleagues in compliance.

The ARVO Commercial Relationships Policy

The ARVO Commercial Relationships Policy states: "Each Paper Presenter is to orally state and display on a slide at the beginning of the presentation all applicable commercial relationship codes, as well as the name of the firm(s) with which a commercial relationship(s) exists for the First Author and each Co-author. At a poster presentation, the presenter must display the relevant commercial relationship(s) code and the name of the firm(s) with which a commercial relationship(s) exists for the First Author and each Co-author. Conformity with this Policy is a requirement." Paper session moderators at the 2005 Annual Meeting will be asked to enforce this policy, and poster presentations will be audited for compliance.

Disclosure of commercial relationships is not only an issue of policy compliance, but has emerged as a significant element in the accreditation of continuing medical education (CME) credits. Paul Kaufman, executive vice president and chair of the Program Committee, commented that "failure on the part of presenters to adequately provide disclosure poses a risk to CME accreditation and the scientific integrity of the Annual Meeting."

The ARVO Recording Policy

The ARVO Recording Policy states: "Recording (photographing, audio taping, or videotaping) any presentation/session is prohibited, except by an ARVO-authorized agent or by First Authors who want to photograph their poster presentations."

Numerous violations of this policy were observed at the 2004 Annual Meeting, prompting the Board to consider mechanisms for stricter enforcement in 2005. Violators are engaging in copyright infringement and theft of intellectual property and risk confiscation of their recording equipment, and/or dismissal from the Annual Meeting as deemed appropriate.

The ARVO Board of Trustees takes these issues very seriously. ARVO will continue to make sure that the policies are well disseminated and requests that members and Annual Meeting attendees be professionally responsible and adhere to these policies.
As reported in the 2003 Winter Newsletter, panels of ARVO members have been developing recommendations to meet the objectives laid out in the ARVO 2003-2008 ARVO Strategic Plan. Panels reported their recommendations to the Board of Trustees (BOT) in April at the Board’s meeting in Fort Lauderdale. The Board received and discussed the recommendations, charging the Long Range Planning Committee (LRPC) with reviewing the recommendations and charging various structural units within ARVO with the task of studying the feasibility of the recommendations and suggesting implementation plans where appropriate. Implementation plans will be submitted to the LRPC for final review against the overall strategic plan before going to the Board (through the Executive and Finance Committees) for final approval.

The following is a listing of the recommendations currently under review. To view the full text of the goals and objectives of the plan, visit www.arvo.org and click the link for "Strategic Plan" under "About ARVO."

**Association Leadership**
- Executive Committee to conduct an evaluation of the performance of staff and the Board, ensuring that appropriate resources are present to advance the strategic goals of the Association. Assess the need and processes for leadership training and development to ensure an adequate pool of future leaders for the Association. (Spring, 2005).

**Chapters and Sections**
- Governance Working Group to explore methods to recognize and encourage cross-sectional scientific interests by developing guidelines to: (1) create Inter-Sectional Groups and (2) establish parameters for their operation within ARVO’s existing governance structure. Develop mechanism for the formation of international chapters that would work to identify their members’ unique needs and develop proposals for Board action to meet them. (Preliminary Report Spring, 2005).

**Trustee Election**
- Nomination Working Group to formalize Trustee nomination process to increase involvement of outgoing trustee, increase transparency and member involvement in the process, and ensure quality candidates for Trustees that reflect the organization’s diversity. (Spring, 2005).

**Committee Involvement**
- Committee Working Group to develop methods to enhance the role of Committees in the business of the Association by emphasizing the role of Trustee liaisons serving on Committees and their reporting responsibilities, identifying an additional time during the year, aside from when the BOT meets, for communication between the BOT and Committees, and developing a process for periodically evaluating the effectiveness of Committees to consider changes in Committee composition or mandate, including whether Committees should be combined or eliminated. Increase the involvement of Members-in-Training in the organization and expose them to leadership roles by evaluating the composition of ARVO’s committees and, where appropriate, inviting a trainee to serve. (Preliminary report, Fall, 2004).

**International Advocacy**
- Special Joint Working Group of the Advocacy and International Members Committees to develop goals for international advocacy and implementation plan for projects advancing these goals. (Spring, 2005).

**Educational Programs**
- Professional Development and Education Committee to establish methods for identifying and evaluating opportunities for ARVO participation in the meetings of other organizations through in kind support, sponsored presentations, or cosponsorship. Establish process for development of short tutorials and incorporate in the Annual Meeting Program. (Spring, 2005).

**Annual Meeting and the Internet**
- Program Committee to study feasibility and need for archiving presentations at the Annual Meeting and if needed, issue a Request For Proposal and review proposals for recording sessions at the Annual Meeting. Consider methods for online presentation of posters prior to and during the Annual Meeting. Develop a more formal process for the proposal, selection, and programming of SIGs. (Spring, 2005).

In the coming weeks, the LRPC will be reviewing recommendations from the Member Services, International Members, Communication, Public Relations, and Advocacy panels. These recommendations will be outlined in the Winter Newsletter.

Member feedback regarding the Plan is welcome at any time. Comments may be submitted to LRPC Chair Gary Abrams, MD or to ARVO Director of Governance and Strategic Initiatives, Robert Rupp (rrupp@arvo.org).

---

**Sarasota Eye Research Conference**
**Ocular Cell and Molecular Biology**

**When:** September 8 – 10, 2005

**Where:** Colony Resort
Right on the beach!
Sarasota, Florida

**Who:**
Attendance is limited.
Contact Rhonda Williams at rwilliams@arvo.org
for more information
As part of the 2003-2008 ARVO Long Range Plan, a Committee of ARVO members reviewed meeting proposals submitted by New Orleans, San Diego, and Fort Lauderdale for ARVO’s traditional meeting dates through 2020. These three cities were selected based on the initial screening of cities identified in a survey of the full ARVO membership (Sarasota, Florida; Miami, Florida; San Diego, California; Los Angeles, California; San Francisco, California; Long Beach, California; New Orleans, Louisiana; and Honolulu, Hawaii).

The Committee reviewed the proposals from the three cities and came to the unanimous conclusion that the additional costs that would be incurred if the meeting were held in New Orleans or San Diego, both to ARVO in terms of meeting space rental and to attendees in terms of travel and lodging cost, and restrictions imposed by sharing space with other groups, were great enough that the Committee recommended that the Annual Meeting continue to be held annually in Fort Lauderdale through 2015. The Board of Trustees accepted this recommendation.

The Committee further recommended, and the Trustees concurred, that this exercise be repeated in five years as a component of the next Strategic Plan.

### Selection Criteria

<table>
<thead>
<tr>
<th>City</th>
<th>Dates Not Available</th>
<th>No Appropriate Space</th>
<th>Cost to ARVO &gt;$150K (Meeting space, transportation, food &amp; beverage)</th>
<th>Hotel Rate Low End &gt;$100</th>
<th>Shared Space with Other Groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fort Lauderdale</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sarasota</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Miami</td>
<td>x</td>
<td>x</td>
<td></td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>San Diego</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Los Angeles</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>San Francisco</td>
<td>x</td>
<td>x</td>
<td></td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Long Beach</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>New Orleans</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>Hawaii</td>
<td>x</td>
<td></td>
<td></td>
<td>x</td>
<td>x</td>
</tr>
</tbody>
</table>

### Meeting Highlights

#### Symposia Topics
- Angiogenesis/Retina
- Cataract
- Cornea and Ocular Surface
- Genetics
- Glaucoma
- Myopia and Refractive Errors/Visual Psychophysics and Physiological Optics
- Epidemiology/International Ophthalmology
- Microbiology and Immunology
- Stem Cell Biology
- Ophthalmic Plastic and Reconstructive Surgery/Pediatric Ophthalmology
- Refractive Surgery

#### Workshops
- Biostatistics in Ophthalmology (New!)
- Understanding Basic Science Research
- How to Write a Successful Grant and Scientific Paper
- Evidence-Based Medicine:
  - How to Evaluate Research Papers (New!)
  - From Randomisation to Masking:
  - How to Conduct a Clinical Trial (New!)
  - How to Design and Conduct An Eye Survey (New!)

#### Important Deadlines:
- Abstract submission: September 30, 2004
- Early registration: December 12, 2004

---

For more information, please contact:
Singapore Eye Research Institute • 11 Third Hospital Avenue #05-00, Singapore 168751
Tel: +65 6322 4500, +65 6322 8311 • Fax: +65 6323 1903, +65 6226 2886
E-mail: seri_arvo@mec.com.sg • Web site: www.seri.com.sg
2005 ARVO Awards Announced

Congratulations to the recipients of the 2005 ARVO Awards. The awards and lectures will be presented during the 2005 ARVO Annual Meeting, May 1-5 in Fort Lauderdale, Florida. Nominations for the 2006 Awards must be submitted by March 3, 2005. For additional information, see www.arvo.org or contact bhollis@arvo.org.

Proctor Medal and Lecture
Henry F. Edelhauser, PhD
Emory University

Friedenwald Award and Lecture
Ronald Klein, MD, MPH
and
Barbara E. K. Klein, MD
University of Wisconsin

Weisenfeld Award and Lecture
C. Stephen Foster, MD
Massachusetts Eye and Ear Infirmary

Cogan Award and Lecture
J. William Harbour, MD
Washington University

ARVO/Pfizer Ophthalmics Translational Research Awards
To be selected in January see below for details.

ARVO Distinguished Service Awards
Sally S. Atherton, PhD
Medical College of Georgia
Joseph C. Besharse, PhD
Medical College of Wisconsin
Oliver J. Braddick, PhD
University of Oxford

Charlotte E. Remé, MD
2004 Proctor Medal Recipient

New ARVO Awards: Call for Nominations Deadline: December 15, 2004!

Through a generous contribution from Pfizer Ophthalmics to The ARVO Foundation, the ARVO/Pfizer Ophthalmics Translational Research Awards have been established. ARVO members are encouraged to nominate their colleagues for these new prestigious ARVO Awards.

Criteria
For excellence in translational research, defined as the application of fundamental scientific discoveries and novel technologies to the development and testing of solutions leading to the prevention, treatment, and diagnosis of eye disease.

Number of Awards
Two awards will be presented annually

Honoraria
$5,000 plus travel, hotel and registration for the ARVO Annual Meeting

Nomination Deadlines
December 15, 2004 (for the 2005 Awards)
March 3, 2005 (for the 2006 Awards)

For complete information on submitting a nomination, visit www.arvo.org/AwardsFunding/awdnom.asp or E-mail bhollis@arvo.org.

Want your meeting posted on the ARVO Calendar? Send details to arvo@arvo.org. Make the ARVO Calendar your #1 Source for Vision related meetings!